Persistence of Vaccine‐Derived Polioviruses among Immunodeficient Persons with Vaccine‐Associated Paralytic Poliomyelitis
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
To estimate long-term poliovaccine virus persistence among immunodeficient patients with vaccine-associated paralytic poliomyelitis (iVAPP), cases reported in the United States during 1975-1997 were reviewed, with subsequent follow-up and virological testing. Six (16.2%) of 37 subjects excreted poliovaccine viruses for > or =6 months. Partial genomic sequencing of their available poliovirus isolates showed considerable divergence from the prototype Sabin strain in all cases. Poliovirus persistence declined over time since the last oral poliovaccine dose: at 6 months, 19.4%; 1 year, 14.3%; 5 years, 4%; and 10 years, 0% (P<.05) of patients. Despite the high prevalence of poliovaccine virus persistence among patients with iVAPP, this group appears to be an unlikely source of poliovirus reintroduction in developed countries because of the rarity and high fatality rate of iVAPP and the possible spontaneous clearance of polioviruses. These results are important for developing "endgame" strategies for the Global Poliomyelitis Eradication Program.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent reports describing highly divergent VDPVs associated with chronic poliovirus infections (10, 69, 88, 90, 113, 123, 216, 223) or with polio outbreaks (84, 169, 177, 226) underscored the earlier concerns and challenged the critical assumption that OPV-derived viruses would not long persist in the community.”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“iVAPP differs markedly from VAPP in immunocompetent individuals, as it is rarely associated with Sabin 3 (14% of cases) and is more frequently associated with Sabin 1 (31% of cases) and Sabin 2 (72% of cases) (some patients were infected with more than one serotype) (90).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“On the other hand, persons with T-cell immunodeficiencies, including those infected with HIV, do not appear to be at an elevated risk for VAPP (74, 90, 183, 186).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“Persons with primary B-cell immunodeficiencies (see below) (168) should not be given OPV because they are at a much higher ( ∼ 3000-fold) risk for VAPP (90, 186).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
In the citing paper
“A much smaller proportion ( ∼ 16%) of iVAPP patients become long-term excretors of iVDPVs (90).”
From VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION (2005) · cites this paper as [90]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Self-citationChronic Enteroviral Meningoencephalitis in Agammaglobulinemic Patients
McKinney, R. E., Katz, S. L., & Wilfert, C. M. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.2.334 · Cited by 452
Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril
Rotbart, H. A., Webster, A. D., & for the Pleconaril Treatment Registry Group (2001) · Clinical Infectious Diseases · doi:10.1086/318452 · Cited by 373
Fine, P. E. M., & Carneiro, I. A. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009924 · Cited by 247
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213
Self-citationKilpatrick, D. R., Nottay, B., Yang, C. F., Yang, S. J., Mulders, M. N., Holloway, B. P., Pallansch, M. A., & Kew, O. M. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.12.2990-2996.1996 · Cited by 172
Self-citation(2000) · PsycEXTRA Dataset · doi:10.1037/e548082006-001 · Cited by 163
Self-citationChronic progressive poliomyelitis secondary to vaccination of an immunodeficient child
Davis, L. E., Bodian, D., Price, D., Butler, I. J., & Vickers, J. H. (1977) · New England Journal of Medicine · doi:10.1056/nejm197708042970503 · Cited by 155
Detection and identification of vaccine-related polioviruses by the polymerase chain reaction
Yang, C.-F., De, L., Holloway, B. P., Pallansch, M. A., & Kew, O. M. (1991) · Virus Research · doi:10.1016/0168-1702(91)90107-7 · Cited by 144
Self-citationPleconaril: a novel antipicornaviral drug
Romero, J. R. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.2.369 · Cited by 131
Bellmunt, A., May, G., Zell, R., Pring-Åkerblom, P., Verhagen, W., & Heim, A. (1999) · Virology · doi:10.1006/viro.1999.0003 · Cited by 128
Stopping poliovirus vaccination after eradication: issues and challenges.
Wood, D. J., Sutter, R. W., & Dowdle, W. R. (2000) · PubMed · doi:10.1590/s0042-96862000000300010 · Cited by 106
Self-citationThe Effect of Diarrhea on Oral Poliovirus Vaccine Failure in Brazil
Posey, D. L., Linkins, R. W., Oliveria, M. J. C., Monteiro, D., & PATRIARCA, P. A. (1997) · The Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s258 · Cited by 59
Hara, M., Saito, Y., Komatsu, T., Kodama, H., Abo, W., Chiba, S., & Nakao, T. (1981) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1981.tb00095.x · Cited by 56
Effect of diarrhea on the humoral response to oral polio vaccination
Myaux, J., UNICOMB, L. E., Besser, R. E., Modlin, J. F., UZMA, A., ISLAM, A. M., & Santosham, M. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00006 · Cited by 53
Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia
Misbah, S. A., Lawrence, P. A., Kurtz, J. B., & Chapel, H. M. (1991) · Postgraduate Medical Journal · doi:10.1136/pgmj.67.785.301 · Cited by 35
Nonparalytic poliovirus infections in patients with severe combined immunodeficiency disease
López, C., Biggar, W. D., Park, B. H., & Good, R. A. (1974) · The Journal of Pediatrics · doi:10.1016/s0022-3476(74)80667-0 · Cited by 30
The potential use of anti-enteroviral drugs in the immunocompromised
Webster, D. (2000) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200012000-00008 · Cited by 6
Cited by
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Self-citationBurns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu295 · Cited by 309
Self-citationCirculating vaccine-derived polioviruses: current state of knowledge.
Kew, O. M., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pallansch, M. A. (2004) · PubMed · doi:10.1590/s0042-96862004000100006 · Cited by 258
“Occasionally, immunodeficient persons exposed to OPV become chronically infected ( 9–11 ), excreting derivatives of the OPV strains for many months or years ( 1, 12–14 ).”
Self-citationCirculation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993
Yang, C.-F., Naguib, T., Yang, S.-J., Nasr, E., Jorba, J., Ahmed, N., Campagnoli, R., van der Avoort, H., Shimizu, H., Yoneyama, T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8366-8377.2003 · Cited by 233
Self-citationVaccine-Acquired Rotavirus in Infants with Severe Combined Immunodeficiency
Patel, N. C., Hertel, P. M., Estes, M. K., de la Morena, M., Petru, A. M., Noroski, L. M., Revell, P. A., Hanson, I. C., Paul, M. E., Rosenblatt, H. M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904485 · Cited by 216
Metadata
- Authors
- Khetsuriani, N., Prevots, D. R., Quick, L., Elder, M. E., Pallansch, M., Kew, O., & Sutter, R. W.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University of California, San Francisco (US)
- National Center for Infectious Diseases (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-15
- Volume
- 188
- Issue
- 12
- Pages
- 1845-1852
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2022472533
- Semantic Scholar
- 83fdf95068386f46d83baefa084cdf25850c5eec
- Cited by
- 110
- References
- 18
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 6 · 2013: 4 · 2012: 7
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- vaccine-derived poliovirus, vaccine-associated paralytic poliomyelitis, immunodeficient patients, polio eradication, virological surveillance
- MeSH terms
- Feces, Female, Follow-Up Studies, Humans, Immunologic Deficiency Syndromes, Infant, Male, Poliomyelitis, Poliovirus Vaccine, Oral, Surveys and Questionnaires, Retrospective Studies, United States, Vaccination, Genetic Variation, Program Evaluation, Genome, Viral, Immunization Programs, Poliovirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.